Study of Botulinum Toxin Type A Injections to Treat Excessive Forehead Sweating in Adults Aged 18 to 40

What this Trial Is About

Primary frontal hyperhidrosis is a chronic condition characterized by excessive sweating in the forehead area, which can greatly affect a persons quality of life due to its visibility and impact on daily activities. This research aims to assess the safety and effectiveness of intradermal injections of Botulinum Toxin Type A for treating this condition. Clinical outcomes will be evaluated using the Hyperhidrosis Disease Severity Scale HDSS, Minors iodine-starch test, and patient satisfaction scores, with follow-up one month after treatment to monitor results and side effects. Participants will receive injections of Botulinum Toxin Type A directly into the affected frontal area. The treatment area is identified using Minors iodine-starch test and divided into a grid for precise injection placement. Each injection delivers 2 units of the toxin, with a total dose ranging from 40 to 80 units depending on the size of the affected region. The injections are given using a fine needle, and the treatment is performed during a single visit. During the study, participants will undergo baseline assessments including the HDSS score and Minors test to map sweating areas. One month after treatment, these assessments will be repeated to measure changes in sweating severity and area. Patient satisfaction will also be recorded using a questionnaire. Safety monitoring will include tracking any adverse effects experienced during the follow-up period. The study is conducted on adults aged 18 to 40 years and aims to provide detailed data on treatment effects and safety over this four-week period.

Botulinum Toxin Type A for Frontal Hyperhidrosis